Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $32.17

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average rating of “Moderate Buy” from the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $32.1667.

DYN has been the topic of several research reports. Morgan Stanley dropped their target price on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Raymond James Financial restated a “strong-buy” rating and set a $37.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 8th. Wall Street Zen cut shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Robert W. Baird lowered their price target on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. Finally, Royal Bank Of Canada dropped their price objective on Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 9th.

Dyne Therapeutics Trading Up 0.1%

Shares of Dyne Therapeutics stock opened at $17.14 on Wednesday. The firm has a market cap of $3.20 billion, a PE ratio of -5.15 and a beta of 1.08. Dyne Therapeutics has a 1 year low of $11.92 and a 1 year high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The stock has a fifty day moving average price of $23.73 and a 200-day moving average price of $20.66.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Equities research analysts anticipate that Dyne Therapeutics will post -3.59 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, Director Jason Rhodes sold 2,160,516 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director owned 428,946 shares of the company’s stock, valued at $10,723,650. This represents a 83.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas Kerr sold 3,745 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $91,190.75. Following the transaction, the insider directly owned 163,854 shares in the company, valued at $3,989,844.90. This represents a 2.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 3,907,314 shares of company stock valued at $94,559,642. Corporate insiders own 9.46% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics during the 1st quarter worth about $26,000. Allworth Financial LP purchased a new stake in shares of Dyne Therapeutics in the second quarter worth about $62,000. Nykredit A S bought a new position in shares of Dyne Therapeutics in the second quarter valued at approximately $113,000. Keating Financial Advisory Services Inc. purchased a new position in Dyne Therapeutics during the second quarter valued at approximately $114,000. Finally, Persistent Asset Partners Ltd bought a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $124,000. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a biotechnology company focused on developing treatments for genetically driven muscle diseases. The company uses its FORCE platform, which is designed to deliver oligonucleotide therapeutics to skeletal muscle and other tissues by combining muscle-targeting antibodies with genetic medicines.

Dyne’s research and development programs are aimed at conditions in which the underlying genetic mutations impair muscle function. Its pipeline has included DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping.